<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39339956</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>16</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month><Day>18</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>Sputnik V-Induced Antibodies against SARS-CoV-2 Variants during the Dissemination of the Gamma Variant in Venezuela.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1480</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v16091480</ELocationID><Abstract><AbstractText>The COVID-19 pandemic was characterized by the emergence and succession of SARS-CoV-2 variants able to evade the antibody response induced by natural infection and vaccination. To evaluate the IgG reactivity and neutralizing capacity of the serum of individuals vaccinated with Sputnik V (105 volunteers vaccinated) against different viral variants. IgG reactivity to the Spike protein (S) was evaluated by ELISA. A plaque reduction neutralization test was performed using different viral variant isolates. At 42 days post-vaccination, the frequency of recognition and reactivity to the S protein of the Omicron variant was lower compared to that of the other variants. In general, a higher average neutralization titer was seen against the ancestral variant compared to the variants, especially Omicron. However, some sera exhibited a higher neutralization titer to the Gamma variant compared to the ancestral variant, suggesting unapparent exposure during the clinical trial. Antibodies induced by Sputnik V can recognize, persist, and neutralize SARS-CoV-2 variants, with Omicron being the one that best evades this response. These results represent a unique report on the humoral response induced by a globally lesser-studied vaccine in terms of efficacy and immune escape, offering insights into developing vaccines targeting unknown coronaviruses.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Franco</LastName><ForeName>Christopher</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-1851-1226</Identifier><AffiliationInfo><Affiliation>Laboratorio de Virología Celular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cornejo</LastName><ForeName>Alejandro</ForeName><Initials>A</Initials><Identifier Source="ORCID">0009-0001-8111-0679</Identifier><AffiliationInfo><Affiliation>Laboratorio de Bioquímica Celular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rodríguez</LastName><ForeName>Mariajosé</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-8898-0546</Identifier><AffiliationInfo><Affiliation>Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García</LastName><ForeName>Alexis</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-2354-0160</Identifier><AffiliationInfo><Affiliation>Instituto de Inmunología, Universidad Central de Venezuela (UCV), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Belisario</LastName><ForeName>Inirida</ForeName><Initials>I</Initials><Identifier Source="ORCID">0000-0002-1183-3927</Identifier><AffiliationInfo><Affiliation>Instituto de Inmunología, Universidad Central de Venezuela (UCV), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mayora</LastName><ForeName>Soriuska</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Instituto de Inmunología, Universidad Central de Venezuela (UCV), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garzaro</LastName><ForeName>Domingo José</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jaspe</LastName><ForeName>Rossana Celeste</ForeName><Initials>RC</Initials><AffiliationInfo><Affiliation>Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hidalgo</LastName><ForeName>Mariana</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Laboratorio de Inmunoparasitología, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Parra</LastName><ForeName>Nereida</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-9445-7682</Identifier><AffiliationInfo><Affiliation>Laboratorio de Fisiología de Parásitos, Centro Biofísica y Bioquímica, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liprandi</LastName><ForeName>Ferdinando</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Laboratorio de Biología de Virus, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zambrano</LastName><ForeName>José Luis</ForeName><Initials>JL</Initials><Identifier Source="ORCID">0000-0001-9884-2940</Identifier><AffiliationInfo><Affiliation>Laboratorio de Virología Celular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rangel</LastName><ForeName>Héctor Rafael</ForeName><Initials>HR</Initials><Identifier Source="ORCID">0000-0001-5937-9690</Identifier><AffiliationInfo><Affiliation>Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pujol</LastName><ForeName>Flor Helene</ForeName><Initials>FH</Initials><Identifier Source="ORCID">0000-0001-6086-6883</Identifier><AffiliationInfo><Affiliation>Laboratorio de Virología Molecular, Centro de Microbiología y Biología Celular, Instituto Venezolano de Investigaciones Científicas (IVIC), Caracas 1020, Venezuela.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>N/A</GrantID><Agency>Ministerio del Poder Popular de Ciencia, Tecnología e Innovación of Venezuela</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>18</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007074">Immunoglobulin G</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D064370">Spike Glycoprotein, Coronavirus</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C000657845">spike protein, SARS-CoV-2</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="Y">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="N">prevention &amp; control</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="Y">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007074" MajorTopicYN="Y">Immunoglobulin G</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D064370" MajorTopicYN="Y">Spike Glycoprotein, Coronavirus</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014687" MajorTopicYN="N" Type="Geographic">Venezuela</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009500" MajorTopicYN="Y">Neutralization Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000008" MajorTopicYN="N">administration &amp; dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">ELISA</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Sputnik V</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">neutralization</Keyword><Keyword MajorTopicYN="N">variants</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study, in the collection, analyses, or interpretation of data, in the writing of the manuscript, or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>18</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39339956</ArticleId><ArticleId IdType="pmc">PMC11437404</ArticleId><ArticleId IdType="doi">10.3390/v16091480</ArticleId><ArticleId IdType="pii">v16091480</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  WHO Data.  [(accessed on 26 March 2024)].  Available online:  https://data.who.int/dashboards/covid19/cases?n=c.</Citation></Reference><Reference><Citation>Barber R.M., Sorensen R.J.D., Pigott D.M., Bisignano C., Carter A., Amlag J.O., Collins J.K., Abbafati C., Adolph C., Allorant A., et al. Estimating Global, Regional, and National Daily and Cumulative Infections with SARS-CoV-2 through Nov 14, 2021: A Statistical Analysis. Lancet. 2022;399:2351–2380. doi: 10.1016/S0140-6736(22)00484-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00484-6</ArticleId><ArticleId IdType="pmc">PMC8993157</ArticleId><ArticleId IdType="pubmed">35405084</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Paulson K.R., Pease S.A., Watson S., Comfort H., Zheng P., Aravkin A.Y., Bisignano C., Barber R.M., Alam T., et al. Estimating Excess Mortality Due to the COVID-19 Pandemic: A Systematic Analysis of COVID-19-Related Mortality, 2020–2021. Lancet. 2022;399:1513–1536. doi: 10.1016/S0140-6736(21)02796-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)02796-3</ArticleId><ArticleId IdType="pmc">PMC8912932</ArticleId><ArticleId IdType="pubmed">35279232</ArticleId></ArticleIdList></Reference><Reference><Citation>Wei L. Retrospect of the Two-Year Debate: What Fuels the Evolution of SARS-CoV-2: RNA Editing or Replication Error? Curr. Microbiol. 2023;80:151. doi: 10.1007/s00284-023-03279-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00284-023-03279-z</ArticleId><ArticleId IdType="pmc">PMC10044072</ArticleId><ArticleId IdType="pubmed">36976379</ArticleId></ArticleIdList></Reference><Reference><Citation>Carabelli A.M., Peacock T.P., Thorne L.G., Harvey W.T., Hughes J., de Silva T.I., Peacock S.J., Barclay W.S., de Silva T.I., Towers G.J., et al. SARS-CoV-2 Variant Biology: Immune Escape, Transmission and Fitness. Nat. Rev. Microbiol. 2023;21:162–177. doi: 10.1038/s41579-022-00841-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41579-022-00841-7</ArticleId><ArticleId IdType="pmc">PMC9847462</ArticleId><ArticleId IdType="pubmed">36653446</ArticleId></ArticleIdList></Reference><Reference><Citation>Sherif Z.A., Gomez C.R., Connors T.J., Henrich T.J., Reeves W.B. Pathogenic Mechanisms of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Elife. 2023;12:e86002. doi: 10.7554/eLife.86002.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.86002</ArticleId><ArticleId IdType="pmc">PMC10032659</ArticleId><ArticleId IdType="pubmed">36947108</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghildiyal T., Rai N., Mishra Rawat J., Singh M., Anand J., Pant G., Kumar G., Shidiki A. Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants. J. Immunol. Res. 2024;2024:9125398. doi: 10.1155/2024/9125398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2024/9125398</ArticleId><ArticleId IdType="pmc">PMC10834093</ArticleId><ArticleId IdType="pubmed">38304142</ArticleId></ArticleIdList></Reference><Reference><Citation>Mykytyn A.Z., Rissmann M., Kok A., Rosu M.E., Schipper D., Breugem T.I., van den Doel P.B., Chandler F., Bestebroer T., de Wit M., et al. Antigenic Cartography of SARS-CoV-2 Reveals That Omicron BA.1 and BA.2 Are Antigenically Distinct. Sci. Immunol. 2022;7:4450. doi: 10.1126/sciimmunol.abq4450.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abq4450</ArticleId><ArticleId IdType="pmc">PMC9273038</ArticleId><ArticleId IdType="pubmed">35737747</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendonça S.A., Lorincz R., Boucher P., Curiel D.T. Adenoviral Vector Vaccine Platforms in the SARS-CoV-2 Pandemic. NPJ Vaccines. 2021;6:97. doi: 10.1038/s41541-021-00356-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41541-021-00356-x</ArticleId><ArticleId IdType="pmc">PMC8342436</ArticleId><ArticleId IdType="pubmed">34354082</ArticleId></ArticleIdList></Reference><Reference><Citation>Fiolet T., Kherabi Y., MacDonald C.J., Ghosn J., Peiffer-Smadja N. Comparing COVID-19 Vaccines for Their Characteristics, Efficacy and Effectiveness against SARS-CoV-2 and Variants of Concern: A Narrative Review. Clin. Microbiol. Infect. 2022;28:202–221. doi: 10.1016/j.cmi.2021.10.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2021.10.005</ArticleId><ArticleId IdType="pmc">PMC8548286</ArticleId><ArticleId IdType="pubmed">34715347</ArticleId></ArticleIdList></Reference><Reference><Citation>Pan American Health Organization  COVID-19 Vaccination in the Americas.  [(accessed on 11 September 2024)].  Available online:  https://ais.paho.org/imm/IM_DosisAdmin-Vacunacion.asp.</Citation></Reference><Reference><Citation>Logunov D.Y., Dolzhikova I.V., Zubkova O.V., Tukhvatullin A.I., Shcheblyakov D.V., Dzharullaeva A.S., Grousova D.M., Erokhova A.S., Kovyrshina A.V., Botikov A.G., et al. Safety and Immunogenicity of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine in Two Formulations: Two Open, Non-Randomised Phase 1/2 Studies from Russia. Lancet. 2020;396:887–897. doi: 10.1016/S0140-6736(20)31866-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)31866-3</ArticleId><ArticleId IdType="pmc">PMC7471804</ArticleId><ArticleId IdType="pubmed">32896291</ArticleId></ArticleIdList></Reference><Reference><Citation>Martynova E., Hamza S., Garanina E.E., Kabwe E., Markelova M., Shakirova V., Khaertynova I.M., Kaushal N., Baranwal M., Rizvanov A.A., et al. Long Term Immune Response Produced by the Sputnikv Vaccine. Int. J. Mol. Sci. 2021;22:11211. doi: 10.3390/ijms222011211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms222011211</ArticleId><ArticleId IdType="pmc">PMC8537212</ArticleId><ArticleId IdType="pubmed">34681885</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikegame S., Siddiquey M.N.A., Hung C.T., Haas G., Brambilla L., Oguntuyo K.Y., Kowdle S., Chiu H.P., Stevens C.S., Vilardo A.E., et al. Neutralizing Activity of Sputnik V Vaccine Sera against SARS-CoV-2 Variants. Nat. Commun. 2021;12:4598. doi: 10.1038/s41467-021-24909-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-24909-9</ArticleId><ArticleId IdType="pmc">PMC8313705</ArticleId><ArticleId IdType="pubmed">34312390</ArticleId></ArticleIdList></Reference><Reference><Citation>Gushchin V.A., Dolzhikova I.V., Shchetinin A.M., Odintsova A.S., Siniavin A.E., Nikiforova M.A., Pochtovyi A.A., Shidlovskaya E.V., Kuznetsova N.A., Burgasova O.A., et al. Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants. Vaccines. 2021;9:779. doi: 10.3390/vaccines9070779.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9070779</ArticleId><ArticleId IdType="pmc">PMC8310330</ArticleId><ArticleId IdType="pubmed">34358195</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaspe R.C., Loureiro C.L., Sulbaran Y., Moros Z.C., D’Angelo P., Rodríguez L., Zambrano J.L., Hidalgo M., Vizzi E., Alarcón V., et al. Introduction and Rapid Dissemination of SARS-CoV-2 Gamma Variant of Concern in Venezuela. Infect. Genet. Evol. 2021;96:105147. doi: 10.1016/j.meegid.2021.105147.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.meegid.2021.105147</ArticleId><ArticleId IdType="pmc">PMC8596652</ArticleId><ArticleId IdType="pubmed">34800714</ArticleId></ArticleIdList></Reference><Reference><Citation>Kudlay D., Svistunov A. COVID-19 Vaccines: An Overview of Different Platforms. Bioengineering. 2022;9:72.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8869214</ArticleId><ArticleId IdType="pubmed">35200425</ArticleId></ArticleIdList></Reference><Reference><Citation>Basta N., Moodie E. COVID-19 Vaccine Tracker.  [(accessed on 30 June 2024)].  Available online:  https://covid19.trackvaccines.org/vaccines/approved/</Citation></Reference><Reference><Citation>Cornejo A., Franco C., Rodríguez M., García A., Belisario I., Mayoría S., Garzaro D.J., Zambrano J.L., Jaspe R.C., Hidalgo M., et al. Humoral Immunity across the SARS-CoV-2 Spike after Sputnik V (Gam-COVID-Vac) Vaccination. Antibodies. 2024;13:41. doi: 10.3390/antib13020041.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib13020041</ArticleId><ArticleId IdType="pmc">PMC11130906</ArticleId><ArticleId IdType="pubmed">38804309</ArticleId></ArticleIdList></Reference><Reference><Citation>Stadlbauer D., Amanat F., Chromikova V., Jiang K., Strohmeier S., Arunkumar G.A., Tan J., Bhavsar D., Capuano C., Kirkpatrick E., et al. SARS-CoV-2 Seroconversion in Humans: A Detailed Protocol for a Serological Assay, Antigen Production, and Test Setup. Curr. Protoc. Microbiol. 2020;57:e100. doi: 10.1002/cpmc.100.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cpmc.100</ArticleId><ArticleId IdType="pmc">PMC7235504</ArticleId><ArticleId IdType="pubmed">32302069</ArticleId></ArticleIdList></Reference><Reference><Citation>Claro F., Silva D., Rodriguez M., Rangel H.R., de Waard J.H. Immunoglobulin G Antibody Response to the Sputnik V Vaccine: Previous SARS-CoV-2 Seropositive Individuals May Need Just One Vaccine Dose. Int. J. Infect. Dis. 2021;111:261–266. doi: 10.1016/j.ijid.2021.07.070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.07.070</ArticleId><ArticleId IdType="pmc">PMC8325383</ArticleId><ArticleId IdType="pubmed">34343704</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez-Nuñez M., del Cepeda M.V., Bello C., Lopez M.A., Sulbaran Y., Loureiro C.L., Liprandi F., Jaspe R.C., Pujol F.H., Rangel H.R. Neutralization of Different Variants of SARS-CoV-2 by a F(Ab′)2 Preparation from Sera of Horses Immunized with the Viral Receptor Binding Domain. Antibodies. 2023;12:80. doi: 10.3390/antib12040080.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/antib12040080</ArticleId><ArticleId IdType="pmc">PMC10740526</ArticleId><ArticleId IdType="pubmed">38131802</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez M.M., Ledesma L., Sanchez L., Ojeda D.S., Rouco S.O., Rossi A.H., Varese A., Mazzitelli I., Pascuale C.A., Miglietta E.A., et al. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time. mBio. 2022;13:e03442-21. doi: 10.1128/mbio.03442-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mbio.03442-21</ArticleId><ArticleId IdType="pmc">PMC8787469</ArticleId><ArticleId IdType="pubmed">35073758</ArticleId></ArticleIdList></Reference><Reference><Citation>Röltgen K., Nielsen S.C.A., Silva O., Younes S.F., Zaslavsky M., Costales C., Yang F., Wirz O.F., Solis D., Hoh R.A., et al. Immune Imprinting, Breadth of Variant Recognition, and Germinal Center Response in Human SARS-CoV-2 Infection and Vaccination. Cell. 2022;185:1025–1040.e14. doi: 10.1016/j.cell.2022.01.018.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.01.018</ArticleId><ArticleId IdType="pmc">PMC8786601</ArticleId><ArticleId IdType="pubmed">35148837</ArticleId></ArticleIdList></Reference><Reference><Citation>Logunov D.Y., Dolzhikova I.V., Shcheblyakov D.V., Tukhvatulin A.I., Zubkova O.V., Dzharullaeva A.S., Kovyrshina A.V., Lubenets N.L., Grousova D.M., Erokhova A.S., et al. Safety and Efficacy of an RAd26 and RAd5 Vector-Based Heterologous Prime-Boost COVID-19 Vaccine: An Interim Analysis of a Randomised Controlled Phase 3 Trial in Russia. Lancet. 2021;397:671–681. doi: 10.1016/S0140-6736(21)00234-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(21)00234-8</ArticleId><ArticleId IdType="pmc">PMC7852454</ArticleId><ArticleId IdType="pubmed">33545094</ArticleId></ArticleIdList></Reference><Reference><Citation>Radion E.I., Mukhin V.E., Kholodova A.V., Vladimirov I.S., Alsaeva D.Y., Zhdanova A.S., Ulasova N.Y., Bulanova N.V., Makarov V.V., Keskinov A.A., et al. Functional Characteristics of Serum Anti-SARS-CoV-2 Antibodies against Delta and Omicron Variants after Vaccination with Sputnik, V. Viruses. 2023;15:1349. doi: 10.3390/v15061349.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15061349</ArticleId><ArticleId IdType="pmc">PMC10301317</ArticleId><ArticleId IdType="pubmed">37376648</ArticleId></ArticleIdList></Reference><Reference><Citation>Claro F., Silva D., Pérez Bogado J.A., Rangel H.R., de Waard J.H. Lasting SARS-CoV-2 Specific IgG Antibody Response in Health Care Workers from Venezuela, 6 Months after Vaccination with Sputnik V. Int. J. Infect. Dis. 2022;122:850–854. doi: 10.1016/j.ijid.2022.06.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2022.06.008</ArticleId><ArticleId IdType="pmc">PMC9176181</ArticleId><ArticleId IdType="pubmed">35690364</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapa D., Grousova D.M., Matusali G., Meschi S., Colavita F., Bettini A., Gramigna G., Francalancia M., Garbuglia A.R., Girardi E., et al. Retention of Neutralizing Response against SARS-CoV-2 Omicron Variant in Sputnik V-Vaccinated Individuals. Vaccines. 2022;10:817. doi: 10.3390/vaccines10050817.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10050817</ArticleId><ArticleId IdType="pmc">PMC9144866</ArticleId><ArticleId IdType="pubmed">35632574</ArticleId></ArticleIdList></Reference><Reference><Citation>Naaber P., Tserel L., Kangro K., Sepp E., Jürjenson V., Adamson A., Haljasmägi L., Rumm A.P., Maruste R., Kärner J., et al. Dynamics of Antibody Response to BNT162b2 Vaccine after Six Months: A Longitudinal Prospective Study. Lancet Reg. Health Eur. 2021;10:100208. doi: 10.1016/j.lanepe.2021.100208.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.lanepe.2021.100208</ArticleId><ArticleId IdType="pmc">PMC8418937</ArticleId><ArticleId IdType="pubmed">34514454</ArticleId></ArticleIdList></Reference><Reference><Citation>Levin E.G., Lustig Y., Cohen C., Fluss R., Indenbaum V., Amit S., Doolman R., Asraf K., Mendelson E., Ziv A., et al. Waning Immune Humoral Response to BNT162b2 Covid-19 Vaccine over 6 Months. N. Engl. J. Med. 2021;385:e84. doi: 10.1056/NEJMoa2114583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2114583</ArticleId><ArticleId IdType="pmc">PMC8522797</ArticleId><ArticleId IdType="pubmed">34614326</ArticleId></ArticleIdList></Reference><Reference><Citation>Greaney A.J., Starr T.N., Gilchuk P., Zost S.J., Binshtein E., Loes A.N., Hilton S.K., Huddleston J., Eguia R., Crawford K.H.D., et al. Complete Mapping of Mutations to the SARS-CoV-2 Spike Receptor-Binding Domain That Escape Antibody Recognition. Cell Host Microbe. 2021;29:44–57.e9. doi: 10.1016/j.chom.2020.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.11.007</ArticleId><ArticleId IdType="pmc">PMC7676316</ArticleId><ArticleId IdType="pubmed">33259788</ArticleId></ArticleIdList></Reference><Reference><Citation>Victora G.D., Nussenzweig M.C. Germinal Centers. Annu. Rev. Immunol. 2022;30:429–457. doi: 10.1146/annurev-immunol-020711-075032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-020711-075032</ArticleId><ArticleId IdType="pubmed">22224772</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner J.S., O’Halloran J.A., Kalaidina E., Kim W., Schmitz A.J., Zhou J.Q., Lei T., Thapa M., Chen R.E., Case J.B., et al. SARS-CoV-2 MRNA Vaccines Induce Persistent Human Germinal Centre Responses. Nature. 2021;596:109–113. doi: 10.1038/s41586-021-03738-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03738-2</ArticleId><ArticleId IdType="pmc">PMC8935394</ArticleId><ArticleId IdType="pubmed">34182569</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudd P.A., Minervina A.A., Pogorelyy M.V., Turner J.S., Kim W., Kalaidina E., Petersen J., Schmitz A.J., Lei T., Haile A., et al. SARS-CoV-2 MRNA Vaccination Elicits a Robust and Persistent T Follicular Helper Cell Response in Humans. Cell. 2022;185:603–613.e15. doi: 10.1016/j.cell.2021.12.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2021.12.026</ArticleId><ArticleId IdType="pmc">PMC8695127</ArticleId><ArticleId IdType="pubmed">35026152</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel R.R., Painter M.M., Apostolidis S.A., Mathew D., Meng W., Rosenfeld A.M., Lundgreen K.A., Reynaldi A., Khoury D.S., Pattekar A., et al. MRNA Vaccines Induce Durable Immune Memory to SARS-CoV-2 and Variants of Concern. Science. 2021;374:abm0829. doi: 10.1126/science.abm0829.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abm0829</ArticleId><ArticleId IdType="pmc">PMC9284784</ArticleId><ArticleId IdType="pubmed">34648302</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim W., Zhou J.Q., Horvath S.C., Schmitz A.J., Sturtz A.J., Lei T., Liu Z., Kalaidina E., Thapa M., Alsoussi W.B., et al. Germinal Centre-Driven Maturation of B Cell Response to MRNA Vaccination. Nature. 2022;604:141–145. doi: 10.1038/s41586-022-04527-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04527-1</ArticleId><ArticleId IdType="pmc">PMC9204750</ArticleId><ArticleId IdType="pubmed">35168246</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakharkar M., Rappazzo G., Wieland-Alter W.F., Hsieh C.L., Wrapp D., Esterman E.S., Kaku C.I., Wec A.Z., Geoghegan J.C., McLellan J.S., et al. Prolonged Evolution of the Human B Cell Response to SARS-CoV-2 Infection. Sci. Immunol. 2021;6:eabg6916. doi: 10.1126/sciimmunol.abg6916.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg6916</ArticleId><ArticleId IdType="pmc">PMC8128290</ArticleId><ArticleId IdType="pubmed">33622975</ArticleId></ArticleIdList></Reference><Reference><Citation>Moriyama S., Adachi Y., Sato T., Tonouchi K., Sun L., Fukushi S., Yamada S., Kinoshita H., Nojima K., Kanno T., et al. Temporal Maturation of Neutralizing Antibodies in COVID-19 Convalescent Individuals Improves Potency and Breadth to Circulating SARS-CoV-2 Variants. Immunity. 2021;54:1841–1852.e4. doi: 10.1016/j.immuni.2021.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2021.06.015</ArticleId><ArticleId IdType="pmc">PMC8249673</ArticleId><ArticleId IdType="pubmed">34246326</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaebler C., Wang Z., Lorenzi J.C.C., Muecksch F., Finkin S., Tokuyama M., Cho A., Jankovic M., Schaefer-Babajew D., Oliveira T.Y., et al. Evolution of Antibody Immunity to SARS-CoV-2. Nature. 2021;591:639–644. doi: 10.1038/s41586-021-03207-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-021-03207-w</ArticleId><ArticleId IdType="pmc">PMC8221082</ArticleId><ArticleId IdType="pubmed">33461210</ArticleId></ArticleIdList></Reference><Reference><Citation>Stebbings R., Armour G., Pettis V., Goodman J. AZD1222 (ChAdOx1 NCov-19): A Single-Dose Biodistribution Study in Mice. Vaccine. 2022;40:192–195. doi: 10.1016/j.vaccine.2021.11.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.11.028</ArticleId><ArticleId IdType="pmc">PMC8637436</ArticleId><ArticleId IdType="pubmed">34865878</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogata A.F., Cheng C.A., Desjardins M., Senussi Y., Sherman A.C., Powell M., Novack L., Von S., Li X., Baden L.R., et al. Circulating Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccine Antigen Detected in the Plasma of MRNA-1273 Vaccine Recipients. Clin. Infect. Dis. 2022;74:715–718. doi: 10.1093/cid/ciab465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciab465</ArticleId><ArticleId IdType="pmc">PMC8241425</ArticleId><ArticleId IdType="pubmed">34015087</ArticleId></ArticleIdList></Reference><Reference><Citation>Aung A., Cui A., Maiorino L., Amini A.P., Gregory J.R., Bukenya M., Zhang Y., Lee H., Cottrell C.A., Morgan D.M., et al. Low Protease Activity in B Cell Follicles Promotes Retention of Intact Antigens after Immunization. Science. 2023;379:eabn8934. doi: 10.1126/science.abn8934.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abn8934</ArticleId><ArticleId IdType="pmc">PMC10041875</ArticleId><ArticleId IdType="pubmed">36701450</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang C., Hart M., Chui C., Ajuogu A., Brian I.J., de Cassan S.C., Borrow P., Draper S.J., Douglas A.D. Germinal Center B Cell and T Follicular Helper Cell Responses to Viral Vector and Protein-in-Adjuvant Vaccines. J. Immunol. 2016;197:1242–1251. doi: 10.4049/jimmunol.1502472.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1502472</ArticleId><ArticleId IdType="pmc">PMC4974488</ArticleId><ArticleId IdType="pubmed">27412417</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Z., Mateus J., Coelho C.H., Dan J.M., Moderbacher C.R., Gálvez R.I., Cortes F.H., Grifoni A., Tarke A., Chang J., et al. Humoral and Cellular Immune Memory to Four COVID-19 Vaccines. Cell. 2022;185:2434–2451.e17. doi: 10.1016/j.cell.2022.05.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2022.05.022</ArticleId><ArticleId IdType="pmc">PMC9135677</ArticleId><ArticleId IdType="pubmed">35764089</ArticleId></ArticleIdList></Reference><Reference><Citation>Nuñez N.G., Schmid J., Power L., Alberti C., Krishnarajah S., Kreutmair S., Unger S., Blanco S., Konigheim B., Marín C., et al. High-Dimensional Analysis of 16 SARS-CoV-2 Vaccine Combinations Reveals Lymphocyte Signatures Correlating with Immunogenicity. Nat. Immunol. 2023;24:941–954. doi: 10.1038/s41590-023-01499-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-023-01499-w</ArticleId><ArticleId IdType="pmc">PMC10232362</ArticleId><ArticleId IdType="pubmed">37095378</ArticleId></ArticleIdList></Reference><Reference><Citation>Islas-Vazquez L., Cruz-Aguilar M., Velazquez-Soto H., Jiménez-Corona A., Pérez-Tapia S.M., Jimenez-Martinez M.C. Effector-Memory B-Lymphocytes and Follicular Helper T-Lymphocytes as Central Players in the Immune Response in Vaccinated and Nonvaccinated Populations against SARS-CoV-2. Vaccines. 2022;10:1761. doi: 10.3390/vaccines10101761.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines10101761</ArticleId><ArticleId IdType="pmc">PMC9607383</ArticleId><ArticleId IdType="pubmed">36298626</ArticleId></ArticleIdList></Reference><Reference><Citation>Yegorov S., Kadyrova I., Negmetzhanov B., Kolesnikova Y., Kolesnichenko S., Korshukov I., Baiken Y., Matkarimov B., Miller M.S., Hortelano G.H., et al. Sputnik-V Reactogenicity and Immunogenicity in the Blood and Mucosa: A Prospective Cohort Study. Sci. Rep. 2022;12:13207. doi: 10.1038/s41598-022-17514-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-17514-3</ArticleId><ArticleId IdType="pmc">PMC9342835</ArticleId><ArticleId IdType="pubmed">35915123</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaspe R.C., Loureiro C.L., Sulbaran Y., Moros Z.C., D’angelo P., Hidalgo M., Rodríguez L., Alarcón V., Aguilar M., Sánchez D., et al. Description of a One-Year Succession of Variants of Interest and Concern of SARS-CoV-2 in Venezuela. Viruses. 2022;14:1378. doi: 10.3390/v14071378.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14071378</ArticleId><ArticleId IdType="pmc">PMC9317613</ArticleId><ArticleId IdType="pubmed">35891359</ArticleId></ArticleIdList></Reference><Reference><Citation>Marklund E., Leach S., Axelsson H., Nystrom K., Norder H., Bemark M., Angeletti D., Lundgren A., Nilsson S., Andersson L.M., et al. Serum-IgG Responses to SARS-CoV-2 after Mild and Severe COVID-19 Infection and Analysis of IgG Non-Responders. PLoS ONE. 2020;15:e0241104. doi: 10.1371/journal.pone.0241104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0241104</ArticleId><ArticleId IdType="pmc">PMC7577439</ArticleId><ArticleId IdType="pubmed">33085715</ArticleId></ArticleIdList></Reference><Reference><Citation>Blanco S., Salomé Konigheim B., Diaz A., Spinsanti L., Javier Aguilar J., Elisa Rivarola M., Beranek M., Collino C., MinSalCba Working Group. FCM-UNC Working Group et al. Evaluation of the Gam-COVID-Vac and Vaccine-Induced Neutralizing Response against SARS-CoV-2 Lineage, P.1 Variant in an Argentinean Cohort. Vaccine. 2022;40:811–818. doi: 10.1016/j.vaccine.2021.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vaccine.2021.12.027</ArticleId><ArticleId IdType="pmc">PMC8685184</ArticleId><ArticleId IdType="pubmed">34953609</ArticleId></ArticleIdList></Reference><Reference><Citation>Cerutti G., Guo Y., Zhou T., Gorman J., Lee M., Rapp M., Reddem E.R., Yu J., Bahna F., Bimela J., et al. Potent SARS-CoV-2 Neutralizing Antibodies Directed against Spike N-Terminal Domain Target a Single Supersite. Cell Host Microbe. 2021;29:819–833.e7. doi: 10.1016/j.chom.2021.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2021.03.005</ArticleId><ArticleId IdType="pmc">PMC7953435</ArticleId><ArticleId IdType="pubmed">33789084</ArticleId></ArticleIdList></Reference><Reference><Citation>Astakhova E.A., Byazrova M.G., Yusubalieva G.M., Kulemzin S.V., Kruglova N.A., Prilipov A.G., Baklaushev V.P., Gorchakov A.A., Taranin A.V., Filatov A.V. Functional Profiling of In Vitro Reactivated Memory B Cells Following Natural SARS-CoV-2 Infection and Gam-COVID-Vac Vaccination. Cells. 2022;11:1991. doi: 10.3390/cells11131991.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11131991</ArticleId><ArticleId IdType="pmc">PMC9265778</ArticleId><ArticleId IdType="pubmed">35805076</ArticleId></ArticleIdList></Reference><Reference><Citation>Astakhova E.A., Morozov A.A., Byazrova M.G., Sukhova M.M., Mikhailov A.A., Minnegalieva A.R., Gorchakov A.A., Filatov A.V. Antigenic Cartography Indicates That the Omicron BA.1 and BA.4/BA.5 Variants Remain Antigenically Distant to Ancestral SARS-CoV-2 after Sputnik V Vaccination Followed by Homologous (Sputnik V) or Heterologous (Comirnaty) Revaccination. Int. J. Mol. Sci. 2023;24:10493. doi: 10.3390/ijms241310493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241310493</ArticleId><ArticleId IdType="pmc">PMC10341525</ArticleId><ArticleId IdType="pubmed">37445671</ArticleId></ArticleIdList></Reference><Reference><Citation>Watson O.J., Barnsley G., Toor J., Hogan A.B., Winskill P., Ghani A.C. Global Impact of the First Year of COVID-19 Vaccination: A Mathematical Modelling Study. Lancet Infect. Dis. 2022;22:1293–1302. doi: 10.1016/S1473-3099(22)00320-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(22)00320-6</ArticleId><ArticleId IdType="pmc">PMC9225255</ArticleId><ArticleId IdType="pubmed">35753318</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam I.C.H., Zhang R., Man K.K.C., Wong C.K.H., Chui C.S.L., Lai F.T.T., Li X., Chan E.W.Y., Lau C.S., Wong I.C.K., et al. Persistence in Risk and Effect of COVID-19 Vaccination on Long-Term Health Consequences after SARS-CoV-2 Infection. Nat. Commun. 2024;15:1716. doi: 10.1038/s41467-024-45953-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-024-45953-1</ArticleId><ArticleId IdType="pmc">PMC10894867</ArticleId><ArticleId IdType="pubmed">38403654</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilks S.H., Mühlemann B., Shen X., Türeli S., LeGresley E.B., Netzl A., Caniza M.A., Chacaltana-Huarcaya J.N., Corman V.M., Daniell X., et al. Mapping SARS-CoV-2 Antigenic Relationships and Serological Responses. Science. 2023;382:eadj0070. doi: 10.1126/science.adj0070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.adj0070</ArticleId><ArticleId IdType="pubmed">37797027</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>